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Giorgio Triolo3, Giuseppe Paolo Segoloni5, Giovanni Camussi4,5,   
Maria Chiara Deregibus4 and Emanuele Gatti1,6* 
1. Introduction 
Haemodialysis (HD) is a life-saving treatment for patients with chronic kidney disease 
(CKD) stage 5. CKD persists as a chronic worldwide epidemic and HD is the more 
frequently (70%) adopted treatment modality. Exponential growth trend continues on a 
global scale. The HD population becomes every year increasingly older (average age: 75 yrs) 
and sicker due to the associated co-morbidities such as cardiovascular disease (heart failure, 
coronary heart disease, and peripheral vascular disease), diabetes, hypertension, and 
peripheral vascular disease. Most of the complications associated with HD involve the 
cardiovascular system (Go et al., 2004; Culleton et al., 1999, Goodkin et al., 2003, Foley 2004; 
Barret, 2002). The evolution in the history of HD technology has greatly helped to make the 
HD procedure a safe and more biocompatible extracorporeal therapy. However, it must be 
admitted that despite significant improvements in HD technology and in the management 
of patients due to a better understanding of uremia toxicity, improvements in dialysis 
technology, better correction of anaemia and metabolic abnormalities, implementation of 
best practice guidelines, no significant improvement has been achieved in patient survival 
over the last decade (Rayner et al., 2004). The extracorporeal circuit offers a large surface of 
contact of the blood with foreign materials, namely the dialysis membrane, the tubings and 
the large volumes of the dialysate. The concept of biocompatibility has greatly evolved in 
the last two decades. Initially, numerous studies focused on the blood-dialyzer membrane 
interaction, leading to the activation of plasma systems (complement, coagulation, 
fibrinolysis). These studies helped in the understanding of some unknown effects occurring 
in the early stages of the HD session leading to pulmonary sequestration of leukocytes 
(mainly neutrophils) that explained the profound neutropenia associated with the 
cuproammonium membranes. The availability of reliable testing of complement-activated 
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products (C3a and C5a and their desarginated products) guided the development of less 
neutropenia-inducing membranes and ultimately to the final development of fully synthetic 
membranes which have very low if at all capacity to induce complement activation. At that 
time, coagulation was an important reason for frequent interruptions and delays in the HD 
sessions. Due to the complex interplay known to occur between the activation of the 
complement and coagulation systems, it became of great interest to try to reduce the 
propensity for intravascular coagulation. The development of high-flux membranes and 
growing awareness of the benefits of convective and convective/diffusive under several 
contexts (intradialytic cardiovascular stability, better control or the uremic status and fluid 
control) gave impetus to a large number of enlightening studies on another mechanism of 
HD bioINcompatibility. The contamination by bacterial products, particularly with the 
widespread use of bicarbonate-based dialysates opened a new era in the field of 
biocompatibility. The formulation of the “interleukin hypothesis” was a posteriori not only 
the basis for further studies on the monocyte stimulation during HD, but also provided a 
link between biocompatibility and chronic inflammation. Basically, the evolution of 
biocompatibility has led us to consider two sides of the same coin: on one side, the biological 
responses at the blood-membrane interface; on the other hand, the consequences derived 
from the contact on the membrane performances (e.g. hydraulic permeability and sieving 
coefficients). 
In this review, we will summarize the most important steps in the evolution from the 
concept of the blood-dialyzer membrane interaction to that of the whole HD system 
compatibility. In face of very recent developments of cell-to-cell communication and signal 
transduction, we will also discuss the new hypothesis for a role of microvesicles (MVs) in 
cell activation, as well as in tissue and vascular repair. We will not deal with other important 
aspects of biocompatibility such as the oxidant stress, the relevant role of additives in 
dialyzer manufacturing, and of leachables and the effects of different sterilization modes.  
2. Blood-membrane interaction: the role of complement, coagulation, kinin-
kallikrein systems and soluble mediators 
2.1 Activation of the complement alternative  pathway  
Early studies on biocompatibility focused on acute hypersensitivity-like reactions which 
in some cases were fatal. Various mechanisms were elucidated. Activation of complement 
was shown by Craddock et al in 1977 (Craddock et al, 1977). Hydroxyl radicals, present on 
the surface of cellulosic membranes, bind with the C3b in the blood and activate the 
alternative pathway leading to the release of potent anaphylatoxins, C3a and C5a. Both 
C3a and C5a and their relative desarginated products induce prompt activation and 
aggregation of polymorphonuclear neutrophils (PMNs) and leukopenia. This is a very 
rapid process reaching a nadir from 15 to 30 min after initiation of dialysis. Aggregates of 
PMNs are sequestered particularly in the lung capillaries. Although the extent of the 
anaphylatoxin generation and of the neutropenia is also patient-dependent, these studies 
failed to find a relationship with chronic clinical trade-offs despite the hypothesis that 
recurrent pulmonary sequestration could induce pulmonary fibrosis. Reduction of the 
hydroxyl groups on the membrane surface or new synthetic polymers reduced the 
activation of the alternative pathway of the complement cascade. Temperature could also 
reduce complement activation (Maggiore Q, personal communication, 1988). Testing 
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complement activation (C3a or C5a plasma levels) by highly sensitive ELISA tests has 
become a standard requirement for the evaluation of biocompatibility ever since along 
with the precise characterization of the polymer structure (Krieter et al, 2008). It also 
became clear that synthetic polymers had a very low neutropenia-inducing effect. In some 
cases such as the polyacrylonitrile membrane, this was also due to the capacity of the 
membrane to adsorb C3b and the anaphylytoxins thus masking in fact complement 
activation (Pascual et al 1993) (Figure 1).  
 
 
Fig. 1. Pathways involved in blood-membrane interactions. LTB4 denotes leukotriene B4, 
PAF, platelet-activating factor, IL-1, interleukin-1, TNF-, tumor necrosis factor. 
2.2 Activation of the coagulation system 
Numerous acquired hemostatic abnormalities have been identified in chronic renal failure. 
HD adds to these disturbances as it repetitively implies turbulent blood flow, high shear 
stress, and contact of blood to artificial surfaces. Anticoagulation in HD is targeted to 
prevent activation of coagulation during the procedure. Most anticoagulant agents inhibit 
the plasmatic coagulation cascade. Still commonly used is unfractionated heparin, followed 
by low-molecular-weight heparin preparations with distinct advantages. Immune-mediated 
heparin-induced thrombocytopenia constitutes a potentially life-threatening complication of 
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heparin therapy requiring immediate switch to nonheparin alternative anticoagulants. 
Danaparoid, lepirudin, and argatroban are currently being used for alternative 
anticoagulation, all of which possess both advantages and limitations. Recently citrate has 
been proposed as anticoagulant in maintenance HD (Wright et al, 2010). In the past, 
empirical strategies reducing or avoiding heparin were applied for patients at bleeding risk, 
whereas nowadays regional citrate anticoagulation is increasingly used to prevent bleeding 
by allowing procedures without any systemic anticoagulation. Avoidance of clotting within 
the whole hemodialyzer circuit is not granted. Specific knowledge of the mechanisms of 
coagulation, the targets of the anticoagulants in use, and their respective characteristics 
constitutes the basis for individualized anticoagulation aimed at achieving full patency of 
the circuit throughout the procedure. Patency of the circuit is an important prerequisite for 
optimal HD quality. Intrinsic coagulation Hageman factor XII as well as other coagulation 
factors are also activated (Fischer, 2007). However, the activation of the coagulation is a very 
complex phenomenon that may be enhanced by different independent factors other than the 
membrane surface per se such as: the dynamics at the dialyzer heads, defects in the hollow 
fibre cutting of the polyurethane, any condition that predisposes for blood to be stagnant. 
The activation of coagulation by a membrane in a dialyzer is difficult to assess given the 
above-mentioned factors and the host's response to the anticoagulation regime put in place 
(Figure 1). 
2.3 Activation of the kinin-kallikrein system 
Surface activation of Factor XII induces the kinin-kallikrein that ensues in the generation of 
bradykinin (Figure 2). 
Bradykinin is physiologically under the tight control of very potent kinases that are able to 
promptly lyse the molecule and inactivate its potent vasodilator activity. In certain 
conditions, however, the lytic effect of this kinase is deficient. This occurs in patients under 
therapy with angiotensin converting enzyme enzyme (ACE) inhibitors. However, there are 
patients who experience hypersensitivity-like phenomena, that can be reconducted to 
bradykinin generation, even in the absence of concomitant therapy with ACE inhibitors. The 
explanation of this phenomenon came from pioneering studies on angio-edema, a rare but 
potentially fatal condition (Adam et al., 2002). These reactions are mainly associated to 
defects in the enzymatic activity of the aminopeptidase P (Figure 2). Bradykinin acts 
through two types of tissue receptors: R1 are mostly located in the skin and respiratory 
tissues (lungs and bronchi), while R2 are mostly found in the gastrointestinal tract. The 
overproduction of bradykinin may lead to two different clinical presentations: the first is 
mainly characterized by a rapid developing skin flushing, hypotension, and dyspnoea. 
These reactions may be mild but very severe, fatal episodes of shock have been described. In 
the second instance, these reactions, which were for some time unexplained, occur after 1 h-
2 hr of HD treatment, may but may be not associated with the use of ACE inhibitors. The 
patient has severe diarrhoea which requires immediate interruption of the extracorporeal 
treatment. This manifestation may unpredictably recur and disappears upon disconnection. 
Bradykinin-induced reaction, may in principle occur following the contact with any foreign 
surface. Their potential, unpredictable severity should call for immediate action even in 
patients with mild forms. The commonest causes have been the use of strongly negative 
surfaces such as AN-69 membranes (Tielemans et al., 1990), or adsorbents used in LDL 
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apheresis (Owen et al., 1994) or in Hemodiafiltration (HDF) with regeneration of the 
ultrafiltrate (Tetta C, Wratten ML, unpublished observation, 2001). The appearance of signs 
and symptoms of a hypersensitivity-related event can be dramatic in the practice of HD. The 
complexity of the causal factors and the underlying mechanisms are often difficult to unveil 
(Arenas et al., 2006). The majority of reported cases have been due to ethylene oxide (ETO) 
(Poothullil et al., 1975), triggered by both immunoglobulin E (IgE) and non-IgE factors 
(Johansson et al., 2001). However, a considerable number of publications have focused on 
other HD substances and materials such as heparins, different dialyser membranes, iron, 
erythropoietin, polyacrylonitrile AN69® high flux membranes, latex, antiseptic or 
formaldehyde (Ebo et al, 2006). Many different underlying mechanisms have been 
postulated. Hypersensitivity reactions have been estimated to occur in ~4/100000 dialysis 
treatments. A postal survey of all HD centres in the UK suggested that 1/20 to 1/50 patients 
may be susceptible to anaphylactoid reaction to a new hemodialyser at some time in 
between, while the risk of reaction occurring with any single HD session is~1/1000 to 
1/5000. Although it is likely that many reactions are unrecognized or unreported, the scale 
of the problem is larger than many nephrologists have suspected (Nicholls et al., 1987). 
 
 
 
 
Fig. 2. Activation of the kinin-kallikrein system and generation of bradykinin (BK) 
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2.3.1 Soluble mediators   
Many soluble mediators are produced and released following the blood-membrane 
interaction. Products of the phospholipase A2 such as platelet-activating factor (PAF) and 
leukotrienes are released by the direct interaction of PMNs and platelets with complement-
activating membranes. Although in the presence of blood, the mechanisms of production of 
PAF and leukotrienes can not be readily differentiated from the activation, as they follow 
the same kinetics, we could show that for PAF for example, its production and release could 
be observed in complement-independent conditions such as in the absence of plasma by 
purified cells incubated with flat HD membranes (Tetta et al., 1996). A large number of 
studies have also suggested the occurrence in the plasma of lytic enzymes normally present 
in the vacuoles of inflammatory cells such as elastases, and metalloenzymes. The release of 
these lytic enzymes is caused by a phenomenon named by cell physiologists as "frustrated 
phagocytosis".  
3. The effect of blood on dialyzer performances 
When blood enters the HD system via the arterial line, a complex interplay of factors alters 
membrane performances e.g. clearances, ultrafiltration rates and sieving coefficients. These 
factors are patient- and system- dependent.  
3.1 Patient-dependent factors 
3.1.1 Albumin: Relevant amount of albumin fragments are detectable in the serum of 
patients undergoing HD. Uremia appears to facilitate the fragmentation of albumin 
and/or the retention of albumin fragments in blood (Donadio et al., 2009). Depending 
on their molecular weight, albumin fragments may be either lost in the dialysate or 
remain trapped in the wall of the hollow fibre. More in general, plasma proteins may 
cause a phenomenon names as “protein fouling”. 
3.1.2 Plasma viscosity which is related (but not exclusively) to albumin, fibrinogen and lipids.  
3.1.3 Free hemoglobin: In vitro data have shown that blood circulation produces an increase 
of up to 280% in free hemoglobin levels and an increase of 320% in electronegative LDL 
(LDL(-) subfraction, a highly atherogenic form of oxidized LDL. The significant 
correlation between LDL(-) and free hemoglobin levels shows the oxidative activity of 
free hemoglobin (Ziouzenkova et al., 1999) (Figure 3).  
3.1.4 System-dependent factors 
3.1.4.1 Several factors are here involved such as the vascular access flow rate, and the pump 
rate and the response of the dialyzer depending on the membrane resistance and 
geometry. As seen from a kinetic perspective, the blood flow, and pressures are on-off 
events which are reflected in a “push-pull” effect on the dialyzer hollow fibre. Although 
these effects are still not completely known, they seem to be relevant on the shear rates, the 
erythrocyte orientation, leading in the worst conditions to predispose to their agglutination 
and clogging of the hollow fibre. Calculating clearances, ultrafiltration rates and sieving 
coefficient using aqueous solution can lead to an overestimate of 30%and is therefore 
hardly informative of the dialyzer behaviour in vivo. Finally, it was shown that sieving 
coefficients may change over the time of treatment rendering the calculation of clearances 
on the basis of the quantization of urea on the ultrafiltrate may also lead to an 
overestimation of the dialyzer performances (Claure-Del Granado et al., 2010).  
www.intechopen.com
 
The Evolution of Biocompatibility: From Microinflammation to Microvesiscles 
 
99 
 
Fig. 3. Microhemolysis is the release of small quantities of hemoglobin (micro- or 
nanomolar) from erythrocytes. The tyrosine of a hemoglobin molecule can undergo a 
transition to a reactive free radical. This can react with other protein tyrosine residues to 
form a dityrosine molecule. Microhemolysis occurs during the HD procedure in which the 
erythrocytes are slightly damaged and tend to „leak“ very small quantities of hemoglobin. 
This is a very common phenomena in HD and should not be confused with gross hemolysis. 
4. The evolution of treatment biocompatibility 
4.1 From system biocompatibility to systemic chronic inflammation 
The concept that inflammation underlines many diseases once considered to be linked to 
degenerative processes has revolutionized the approach to the research into the 
pathogenesis and new therapeutics alike. In the field of cardiovascular disease, the process 
of endothelial dysfunction, vascular damage and atherosclerosis is now seen as a continuum 
(Libby et al., 2002). Cardiovascular disease is among the leading cause of morbidity and 
mortality in CKD patients on maintenance HD (US Renal Data System, 1997; Parfey & Foley, 
1999). Even before reaching the state of chronic kidney disease Stage 5, patients with chronic 
renal failure present signs of chronic inflammation. Once patients are on HD, the risk of 
cardiovascular death is approximately 30 times higher than in the general population, and 
still remains 10 to 20 times higher after stratification for age, gender, and presence of 
diabetes. Traditional risk factors seem inadequate to explain the remarkable prevalence of 
cardiovascular disease observed in the uremic population (Foley et al 1998).  
4.1.1.1 Systemic Chronic Inflammation  
Inflammatory mechanisms play a relevant role in the development and progression of 
atherosclerosis (Ross, 1999) and heart failure (Vasan et al., 2003). Epidemiological studies in 
the general population have shown that even minor elevations of C-reactive protein (CRP), 
an acute phase reactant that markedly increases during an inflammatory response (Ridker 
PM, et al., 1997) predict the development of coronary heart disease and cardiac failure 
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(Liuzzo et al 1994, Lagrand et al., 1999, Badht et al, 2002). C-reactive protein may directly 
promote the development of atherosclerosis, through complement activation, tissue damage 
and activation of endothelial cells. Recent studies performed in CKD patients have shown 
that CRP is a strong predictor of cardiovascular death (Stenvinkel, 2001, Kaysen, 2005). The 
link between CRP and cardiovascular risk was initially thought to be indirect, reflecting 
circulating CRP only to the extent of the acute phase reaction in response to nonspecific 
stimuli such as confounding risk factors, atherosclerosis, vascular injury, ischemia and 
necrosis. (Figure 4). 
 
 
Fig. 4. Acute phase response is a defence response which occurs as a consequence of an 
inflammatory stimulus occurring in the blood or at tissue level. The enhanced production of 
interleukin-6 (IL-6), the most potent inducer of this reaction at the level of the liver, triggers 
the synthesis of newly synthesized proteins, e.g., C-reactive protein (which plasma levels 
may increase up to 50-to 100-fold the normal levels) as well as to the shut-down of the 
translation of genes coding for proteins, e.g., albumin. 
Stenvinkel et al (1999) first convincingly showed that the malnutrition-inflammation 
complex syndrome described as MIA syndrome is associated with the highest mortality 
rates in ESRD. Their results were confirmed and extended (Panichi et al. 2008). As reviewed 
by Stenvinkel & Barany (2002), there is consensus on a link between CKD and inflammation. 
A number of studies have highlighted the association between increased inflammatory 
indexes and a reduced response to Erythropoietin-stimulating agents (ESAs), in particular, 
high CRP levels were found in HD patients requiring higher ESAs doses (Singh et al., 2007; 
Bradbury et al. 2009). However, the association between ESAs resistance and increased CRP 
levels (Barany et al. 1997; Gunnell et al. 1999) is unclear. Plasma IL-6 rather than CRP seem 
to better predict outcomes in CKD patients (Panichi et al., 2004). Various possible 
explanations may underline the advantage of IL-6 over CRP as a predictor of ESAs 
resistance. One possibility is that IL-6, being located upstream in the cascade of events 
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which lead to the synthesis of many acute-phase reactants, is a better marker for the 
inflammatory burden affecting the development of CVD (Panichi et al., 2011). A frequently 
asked question is what is the contribution of HD bioincompatibility to the chronic 
inflammatory state. In this context, the evolution of HD technology has moved the focus 
from membrane bioincompatibility only to a more complex and integrated view of the HD 
system. The possibility that HD may be shift to a “cardioprotective’’ therapy is inherent to 
new technologies in machines, water treatment, dialysis fluids and blood tubings. 
4.1.1.2 The Interleukin Hypothesis  
Originally introduced as an elegant concept in 1986 (Bingel et al., 1986), the “interleukin 
hypothesis” was first coined to indicate the production of interleukin-1, the endogenous 
pyrogen as produced by the result of complement-activated mononuclear cells. Indeed, 
the interleukin hypothesis explained much more than was initially predictable. Several 
studies have ever since reported an increased cytokine production secondary to blood 
interaction with contaminated dialysate. Interleukin-1 (IL-1), tumor necrosis factor-a 
(TNF-a) and mainly IL-6 are the 3 proinflammatory cytokines that are involved in the 
pathogenetic aspects of HD-related disease (as reviewed by Lonnemann, 2004, Panichi et 
al., 2000 (Figure 5).  
 
 
Fig. 5. Here are schematically depicted the mechanisms related to the 
backdiffusion/backfiltration of bacteria-derived contaminants from the dialysate into the 
blood. Their interaction with circulating monocytes/macrophages leads to the activation of 
innate immunity and to the attendant triggering of proinflammatory cytokines (interleukin-
1 (IL-1), tumor necrosis factor-. Abbreviations: CIS, cytokine-inducing substances; LAL, 
Limulus amoebocyte lysate, UF, ultrafiltrate. 
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The proposed mechanisms include blood interaction with endotoxins from the 
contaminated dialysate through HD membranes. A large number of studies have greatly 
contributed to increasing our knowledge in the mechanisms of endotoxin transfer across the 
membrane In fact, when using high permeability membranes, backfiltration and 
backdiffusion occur and have ebeen extensively described (Fiore & Ronco, 2007, Ronco, 
2007). Thus, the transmembrane passage of endotoxins or other cytokine stimulating 
substances (CIS) occurs during HD (Schindler et al., 2004, Tetta et al., 2006). The reduction of 
backfiltration of standard dialysate may reduce the plasma concentration of IL-1ra, a 
sensitive indicator of inflammation in HD patients (Dinarello personal communication, 2004), 
and IL-1 (Panichi et al., 1998). Studies on large groups of patients have shown that high-
volume exchange HDF, a treatment in which dialysate backfiltration is minimal, if any, is 
associated with significantly lower CRP plasma values (Panichi et. 1998). Comparing in a 
double cross-over study patients treated with high-flux and on line HDF using ultrapure 
dialysate and infusate, it was shown that a significant reduction of pro-inflammatory 
CD14+/CD16+ mononuclear subset (Carracedo et al., 2006) occurs in on line HDF. These 
studies emphasize that the convective component has an additional anti-inflammatory 
effects (Ramirez et al., 2007). 
The new technology of pyrogen-adsorbing, non-complement activating, high-permeability 
synthetic membrane and dedicated machines (Tetta et al., 2011), as well as the awareness of 
the deleterious effects derived from contamination of dialysis fluids has reduced the clinical 
impact to a periodic microinflammatory stimulus. Undoubtedly, the availability of monitors 
for on-line HDF and its increased popularity have spurred more restrictive measures on 
safety issues and monitoring. Water quality is a mandatory issue. The safety of online HDF 
has been shown repeatedly in several monocenter  (Canaud et al., 1998, Pizzarelli et al., 1998 
and multicenter studies (Canaud et al., 2001,Vaslaki  et al., 2000). 
Nowadays, the philosophy of ‘‘ultrapure dialysate’’is in common practice (Kessler et  
al., 2002). The clinical, consolidated experience on line HDF warrants well-defined 
procedures and leaves no space for ‘‘experiments’’ in what is now routine (Canaud et al, 
2011). The ‘‘hemocompatibility network’’ should eventually prevent the periodic 
microinflammation induction through the implementation of rigid protocols of disinfection 
and maintenance of water-treatment systems and HD monitors (Cappelli et al., 2006; Kessler 
et al. 2002).  
5. Microvesicles: their nature, release and pathophysiological relevance  
A chronic inflammatory state has been widely documented since the early stages of CKD 
and becomes more pronounced in those with CKD stage V undergoing HD. Oxidant stress 
(Wratten et al., 2000, Morena et al. 2011), endothelial dysfunction (Recio-Mayoral et al., 
2011), high circulating cytokine-producing monocyte subpopulation (Ramirez et al., 2006), 
reduced number and/or impaired function of endothelial progenitor cells (Krenning et al., 
2009), are today considered as hallmarks of vascular damage and defective repair. Uremia 
also causes telomere shortening and premature cellular senescence of immunocompetent 
cells (Jimenez et al, 2005). In recent years, increasing attention has been drawn by the 
awareness of the pathophysiologic role of small, circular membrane fragments named as 
Microvesiscles (MVs) (Ratajczak  et al., 2006) (Figure 6). 
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Fig. 6. 
For long time MVs were considered to be inert cellular debris. The frequently observed 
vesicles by electron microscopy in the interstitial space of tissues or in blood were 
considered as the consequence of cell damage or the result of dynamic plasma membrane 
turnover (Siekevitz et al., 1972). As the vesicle population detectable both in vitro and in vivo 
is a mixed population of exosomes and shedding vesicles, we will refer to  them collectively 
as MVs. Released MVs may remain in the extracellular space in proximity of the place of 
origin or may enter into the biological fluids reaching distant sites. This may explain the 
presence of MVs in plasma, urine, milk and cerebrospinal fluid. The bulk of MVs present in 
the circulation is derived from platelets (George, 1982), and in less extent from other blood 
cells and endothelial cells (Martinez et al., 2005). The MVs derived from platelets are also 
designed as microparticles while those derived from polymorphonuclear leukocytes are also 
named ectosomes (Hess et al., 1999). Finally, MVs released during morphogenesis of 
multicellular organisms are indicated as argosomes (Greco et al., 2001). Besides normal cells, 
also tumor cells may release MVs and in patients suffering for neoplastic diseases tumor-
derived MVs may be detected within the biological fluids (Kim et al, 2003, Iero et al., 2008). 
Therefore, MVs are an assorted population, differing in cellular origin, number, size and 
antigenic composition (Diamant et al., 2004) shed by various cell types in physiological and 
pathological conditions. The release of MVs may be constitutive or consequent to cell 
activation by soluble agonists, by physical or chemical stress such as the oxidative stress and 
hypoxia, and by shear stress (Ratajczak et al., 2006). Exosomes have an endosome origin and 
are a rather homogenous population with a size ranging from 30 to 120nm (7). They are 
stored as intraluminal vesicles within multivesicular bodies of the late-endosome and are 
released when these multivesicular bodies fuse with the cell membrane. Our knowledge on 
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the mechanism of assembly and sorting of the exosomes is only partial, due to the fact that a 
common sorting signal for all cell types has not so far been identified (Johnstone et al., 2006).  
Shedding vesicles are usually larger than exosomes with size ranging from 100nm to 1m. 
Formation of shedding vesicles takes place from the budding of small cytoplasmic 
protrusions followed by their detachment from the cell surface. This process is dependent 
on calcium influx, calpain and cytoskeleton reorganization. 
5.1 MV biological activities 
It is now recognized that MVs are an integral part of the intercellular microenvironment and 
may act as regulators of cell-to-cell communication. This concept is based on the observation 
that MVs released from a given cell type may interact through specific receptor-ligands with 
other cells leading to target cell stimulation directly or by transferring surface receptors 
(Janowska-Wieczorek et al., 2001,  Morel et al., 2004). This interaction may either be limited 
to a receptor-mediated binding to the surface of target cells forming a platform for assembly 
of multimolecular complexes or leading to cell signaling, either be followed by 
internalization as result of direct fusion or endocytic uptake by target cells (Cocucci et al., 
2008). Once internalized, MVs can fuse their membranes with those of endosomes, thus 
leading to a horizontal transfer of their content in the cytosol of target cells. Alternatively, 
they may remain segregated within endosomes and be transferred to lysosomes or 
dismissed by the cells following the fusion with the plasmamembrane, thus leading to a 
process of transcytosis. It was proposed that MV-mediated cell-to-cell communication 
emerged very early during evolution as a template for the development of further more 
refined mechanisms of cell communication (Ratajczak et al., 2006). MVs may influence the 
behavior of target cells in multiple ways.  
5.1.1 MVs may act as signaling complexes by direct stimulation of target cells (Ratajczak 
et al., 2006, Cocucci et al., 2008). MVs derived from platelets, for instance, play an 
important role in coagulation as their phosphatidylserine-enriched membranes provide 
a surface for assembly of clotting factors (Zwaal et al., 2004). After activation, platelets 
shed MVs coated with tissue factor which may interact with macrophages, neutrophils 
and other platelets by ligation with molecules expressed on the surface of these cells 
such as P-selectin (Polgar et al., 2005). On the other hand, MVs released from 
neutrophils express activated Mac-1 able to induce platelet activation (Andrews & 
Berndt, 2004). Moreover, platelet-derived MVs, besides coagulation, trigger various cell 
responses as they activate endothelial cells (Barry et al., 1997), polymorphonuclear 
neutrophils (Miyhamoto et al., 1988) and monocytes (Barry et al., 1999). . 
5.1.2 MVs may act by transferring receptors between cells. The transferring of receptors 
between cells is supported by the observation that bystander B cells rapidly acquire 
antigen receptors from activated B cells by a membrane transfer (Quah et al., 2008). 
5.1.3 MVs may deliver proteins within the target cells. An example of this mechanism is 
the recently reported MV-mediated transfer of a cell death message via encapsulated 
caspase-1 (Sarkar et al., 2009). It has been found that endotoxin stimulated monocytes 
induce the cell death of vascular smooth muscle cells by releasing MVs containing 
caspase-1. This trans-cellular apoptosis induction pathway depends on the function of 
the delivered caspase-1 within the target cells. It has been also suggested that MVs may 
contribute to dissemination of certain infective agents, such as HIV or prions (Facler & 
Peterlin, 2000, Fevrier et al., 2004).  
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5.1.4 MVs may mediate a horizontal transfer of genetic information. The occurrence of 
epigenetic changes has been frequently reported in co-culture conditions. An 
explanation of this phenomenon is the transfer of genetic information between cells. We 
demonstrated that MVs derived from human endothelial progenitors (EPC) can also act 
as a vehicle for mRNA transport among cells (Deregibus et al., 2007). MVs generated 
from EPC were incorporated in normal endothelial cells by interaction with 4- and 1-
integrins expressed on their surface and activated an angiogenic program. Besides 
mRNA, MVs may transfer microRNAs (miRNA) to target cells (Yuan et al., 2009). Since 
miRNAs are naturally occurring regulators of protein translation, this observation 
opens the possibility that stem cells can alter the expression of genes in neighbouring 
cells by transferring microRNAs contained in MVs. We recently characterized miRNA 
shuttled by MVs released by human adult mesenchymal stem cells (MSCs) (Collino et 
al., 2010). Hierarchical clustering and similarity analysis of microRNAs showed that 
microRNA compartmentalization and secretion by MVs are both highly regulated 
processes. 
5.2 Microvesicles in CKD 
The biologic role of MVs and their implication in pathophysiology depends on the several 
factors namely the cell of origin, their phenotype, the genetic material (mRNA and 
microRNA) and the target cells. In CKD, several studies have accrued evidence that MVs or 
MPs could participate to the vascular damage and the evolution of the atherosclerotic lesion.  
5.2.1 Circulating platelet-derived microparticles (PMPs) with procoagulant activity are 
considered a potential cause of thrombosis in uremic patients undergoing HD (Ando et 
al., 2002). Elevated counts of circulating PMPs have been reported in association with 
thrombotic disorders, such as cerebrovascular accidents (Katopodis et al., 1997), 
unstable angina (Katopodis et al., 1997), and acute myocardial infarction (Gawaz et al., 
1996). In addition, PMPs that adhered to vascular endothelium and leukocytes activate 
such cells and transport their chemical mediators to those cells, potentially leading to 
the development of thrombosis and atherosclerosis (Mallat et al., 1999, Barry et al., 
1997).  
5.2.2 Endothelial MVs (EMVs) - Treatment modalities that reduce the inflammatory 
potential of the cells originating MVs have interestingly been correlated with a 
decreased number of endothelial microparticles (Carracedo et al., 2005, Ramirez et al., 
2005). Circulating EMPs have recently been reported to correlate with impaired 
vascular function in HD patients (Faure et al., 2006). A recent study showed an increase 
in the percentage of CD14+CD16+ monocytes in CKD-NonD and HD patients. In PD 
patients, regardless of RRF, the percentage of CD14+CD16+ was similar to controls 
(Merino et al., 2010). It is interesting to note that HD patients displayed significantly 
higher apoptotic EMPs and VEGF levels than the two PD and CKD-non dialyszed 
groups. In contrast, there were no differences between CKD-NonD and PD groups. In 
CKD-non dialyszed and HD patients, the percentage of CD14+CD16+ was correlated 
with endothelial damage. It appears that PD, compared with HD, reduces but does not 
fully prevent the endothelial damage induced by uremia, in spite of presenting a 
microinflammatory status similar to that of the controls. The role of EMVs is still to be 
elucidated in the complex unbalance observed in CKD patients between circulating 
endothelial cells and endothelial progenitor cells.  
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5.2.3 MVs in treatment modalities  
Preliminary studies in our laboratory have shown an interesting trend in the reduction of 
total MVs in a cross-over clinical study when patients shifted from high-flux HD to on-line 
HDF (Figure 7).  
 
 
Fig. 7. Total MVs count in patients on maintenance HD. In a cross-over design, 8 patients 
were started on bicarbonate HD (black columns) and 8 patients on on-line HDF (grey 
columns). MVs were counted by cytofluorimetry. MVs were also characterized (data not 
shown) by the following specific markers: CD62P, CD41, CD42, CD31, for platelets; CD45, 
for leukocytes; CD31, CD146, CD144 for the endothelium: CD235 and CD242 (ICAM 4), for 
erythrocytes. 
More studies are needed to better assess the relevance of these observations and to better 
characterize the type and biological effects of the MVs. It is still to be fully elucidated 
whether MVs are a consequence or a cause of disease. Increasing evidence for their 
pathophysiologic role in other human diseases such as sepsis and tumors (Camussi et al., 
2011) is rapidly accruing. Many points require further investigation. i. The stimuli and the 
molecular pathways that regulate the assembly within MVs of the biological active 
molecules that they shuttle. ii. The stimuli that trigger their release. iii. The surface receptors 
that may confer selective specificity. iv. The full diagnostic potential of MVs in different 
pathological conditions. v. The strategy to inhibit formation or to remove from circulation 
potentially harmful MVs. The recognition of MVs has opened a new era and new 
perspectives of investigation also in biocompatibility of extracorporeal treatments. 
6. Conclusions 
The outlook of more biocompatible and physiological dialysis is today confronted with a 
older and sicker population in need of maintenance HD. The knowledge of biological 
mechanisms operating at the system level will be approached with the help of improved 
technologies hopefully able to reduce the deleterious effect of the repetitive contact with a 
foreign surface and to insure optimal performances for the elimination of small and middle 
molecule solutes. Advances in dialyzer membranes and geometries, as well as blood tubings 
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together with new concepts in machine technology have already shown their great potential  
to improve survival and cardiovascular stability.  
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